Paul Diaz | President and CEO |
Nicole Lambert | COO |
Bryan Riggsbee | CFO |
Mark Verratti | Chief Commercial Officer. |
Matthew Scalo | SVP, IR |
Andrew Cooper | Raymond James |
Dave Delahunt | Goldman Sachs |
John Kim | Bank of America |
Jack Meehan | Nephron Research |
Puneet Souda | SVB |
Jacob Krahenbuhl | Stephens |
Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call.
During the call, we will review the financial results we released today. And afterwards, we will host a question-and-answer session.
Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our Web site at investor.myriad.com.